129.145 USD
+1.6 (+1.25%)
Taking everything into account, ILMN scores 6 out of 10 in our fundamental rating. ILMN was compared to 58 industry peers in the Life Sciences Tools & Services industry. ILMN has an excellent profitability rating, but there are some minor concerns on its financial health. ILMN may be a bit undervalued, certainly considering the very reasonable score on growth This makes ILMN very considerable for value investing!
1. Profitability
1.1 Basic Checks
ILMN had positive earnings in the past year.
ILMN had a positive operating cash flow in the past year.
In multiple years ILMN reported negative net income over the last 5 years.
ILMN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ILMN's Return On Assets of 11.38% is amongst the best of the industry. ILMN outperforms 91.38% of its industry peers.
ILMN's Return On Equity of 29.53% is amongst the best of the industry. ILMN outperforms 96.55% of its industry peers.
ILMN's Return On Invested Capital of 16.40% is amongst the best of the industry. ILMN outperforms 91.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROIC | 16.4% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ILMN (16.39%) is better than 89.66% of its industry peers.
The Operating Margin of ILMN (20.41%) is better than 86.21% of its industry peers.
ILMN's Operating Margin has declined in the last couple of years.
ILMN has a Gross Margin of 66.74%. This is amongst the best in the industry. ILMN outperforms 87.93% of its industry peers.
In the last couple of years the Gross Margin of ILMN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% |
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ILMN is still creating some value.
The number of shares outstanding for ILMN remains at a similar level compared to 1 year ago.
The number of shares outstanding for ILMN has been increased compared to 5 years ago.
Compared to 1 year ago, ILMN has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 4.24 indicates that ILMN is not in any danger for bankruptcy at the moment.
ILMN has a better Altman-Z score (4.24) than 74.14% of its industry peers.
The Debt to FCF ratio of ILMN is 1.99, which is an excellent value as it means it would take ILMN, only 1.99 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.99, ILMN belongs to the top of the industry, outperforming 87.93% of the companies in the same industry.
A Debt/Equity ratio of 0.42 indicates that ILMN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.42, ILMN is in line with its industry, outperforming 41.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Altman-Z | 4.24 |
ROIC/WACC1.63
WACC10.05%
2.3 Liquidity
A Current Ratio of 1.43 indicates that ILMN should not have too much problems paying its short term obligations.
ILMN's Current ratio of 1.43 is on the low side compared to the rest of the industry. ILMN is outperformed by 79.31% of its industry peers.
ILMN has a Quick Ratio of 1.12. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
ILMN has a worse Quick ratio (1.12) than 70.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
ILMN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 152.02%, which is quite impressive.
ILMN shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -17.93% yearly.
Looking at the last year, ILMN shows a decrease in Revenue. The Revenue has decreased by -2.32% in the last year.
ILMN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.29% yearly.
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
3.2 Future
The Earnings Per Share is expected to grow by 24.49% on average over the next years. This is a very strong growth
Based on estimates for the next years, ILMN will show a small growth in Revenue. The Revenue will grow by 3.93% on average per year.
EPS Next Y93.48%
EPS Next 2Y43.68%
EPS Next 3Y33.01%
EPS Next 5Y24.49%
Revenue Next Year-1.07%
Revenue Next 2Y0.57%
Revenue Next 3Y2.22%
Revenue Next 5Y3.93%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 29.62, ILMN can be considered very expensive at the moment.
74.14% of the companies in the same industry are more expensive than ILMN, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of ILMN to the average of the S&P500 Index (26.15), we can say ILMN is valued inline with the index average.
The Price/Forward Earnings ratio is 25.54, which means the current valuation is very expensive for ILMN.
77.59% of the companies in the same industry are more expensive than ILMN, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.22, ILMN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.62 | ||
| Fwd PE | 25.54 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ILMN is valued cheaper than 82.76% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ILMN is valued cheaper than 87.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.73 | ||
| EV/EBITDA | 17.37 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ILMN may justify a higher PE ratio.
A more expensive valuation may be justified as ILMN's earnings are expected to grow with 33.01% in the coming years.
PEG (NY)0.32
PEG (5Y)N/A
EPS Next 2Y43.68%
EPS Next 3Y33.01%
5. Dividend
5.1 Amount
ILMN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ILMN (12/3/2025, 12:05:09 PM)
129.145
+1.6 (+1.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners102.96%
Inst Owner Change1.54%
Ins Owners0.18%
Ins Owner Change-0.36%
Market Cap19.73B
Revenue(TTM)4.29B
Net Income(TTM)703.00M
Analysts72.86
Price Target120.47 (-6.72%)
Short Float %4.29%
Short Ratio3.58
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.9%
Min EPS beat(2)12.52%
Max EPS beat(2)15.27%
EPS beat(4)3
Avg EPS beat(4)5.34%
Min EPS beat(4)-7.76%
Max EPS beat(4)15.27%
EPS beat(8)6
Avg EPS beat(8)97.15%
EPS beat(12)10
Avg EPS beat(12)231.96%
EPS beat(16)13
Avg EPS beat(16)178.01%
Revenue beat(2)0
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.66%
Min Revenue beat(4)-1.21%
Max Revenue beat(4)-0.18%
Revenue beat(8)3
Avg Revenue beat(8)-0.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.57%
Revenue beat(16)5
Avg Revenue beat(16)-0.78%
PT rev (1m)5.82%
PT rev (3m)5.17%
EPS NQ rev (1m)3.76%
EPS NQ rev (3m)2.65%
EPS NY rev (1m)3.19%
EPS NY rev (3m)2.83%
Revenue NQ rev (1m)0.81%
Revenue NQ rev (3m)0.63%
Revenue NY rev (1m)0.37%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.62 | ||
| Fwd PE | 25.54 | ||
| P/S | 4.6 | ||
| P/FCF | 19.73 | ||
| P/OCF | 17.59 | ||
| P/B | 8.29 | ||
| P/tB | 18.92 | ||
| EV/EBITDA | 17.37 |
EPS(TTM)4.36
EY3.38%
EPS(NY)5.06
Fwd EY3.92%
FCF(TTM)6.54
FCFY5.07%
OCF(TTM)7.34
OCFY5.69%
SpS28.06
BVpS15.58
TBVpS6.83
PEG (NY)0.32
PEG (5Y)N/A
Graham Number39.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROCE | 20.76% | ||
| ROIC | 16.4% | ||
| ROICexc | 23.54% | ||
| ROICexgc | 43.23% | ||
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% | ||
| FCFM | 23.32% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Debt/EBITDA | 0.86 | ||
| Cap/Depr | 44.36% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.57% | ||
| Profit Quality | 142.25% | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 4.24 |
F-Score7
WACC10.05%
ROIC/WACC1.63
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
EPS Next Y93.48%
EPS Next 2Y43.68%
EPS Next 3Y33.01%
EPS Next 5Y24.49%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
Revenue Next Year-1.07%
Revenue Next 2Y0.57%
Revenue Next 3Y2.22%
Revenue Next 5Y3.93%
EBIT growth 1Y154.36%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year30.85%
EBIT Next 3Y15.15%
EBIT Next 5Y16.22%
FCF growth 1Y495.24%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y179.8%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%
ILLUMINA INC / ILMN FAQ
Can you provide the ChartMill fundamental rating for ILLUMINA INC?
ChartMill assigns a fundamental rating of 6 / 10 to ILMN.
What is the valuation status for ILMN stock?
ChartMill assigns a valuation rating of 7 / 10 to ILLUMINA INC (ILMN). This can be considered as Undervalued.
How profitable is ILLUMINA INC (ILMN) stock?
ILLUMINA INC (ILMN) has a profitability rating of 7 / 10.
How financially healthy is ILLUMINA INC?
The financial health rating of ILLUMINA INC (ILMN) is 5 / 10.
Can you provide the expected EPS growth for ILMN stock?
The Earnings per Share (EPS) of ILLUMINA INC (ILMN) is expected to grow by 93.48% in the next year.